Navigation Links
High antiretroviral therapy adherence associated with lower health care costs
Date:1/6/2010

High antiretroviral therapy adherence, which has been shown to be a major predictor of HIV disease progression and survival, is now associated with lower health care costs, according to researchers at the Johns Hopkins Bloomberg School of Public Health. Researchers examined the effect of antiretroviral therapy adherence on direct health care costs and found that antiretroviral therapy improves health outcomes for people infected with HIV, saving a net overall median monthly health care cost of $85 per patient. The results are featured in the January 5, 2010, issue of the Annals of Internal Medicine.

"Our analysis found that greater antiretroviral therapy adherence was associated with lower direct health care costs for HIV-infected adults who received care through a large HIV/AIDS disease management program in South Africa," said Jean B. Nachega, MD, PhD, MPH, lead author of the study, associate scientist in the Bloomberg School's Department of International Health, professor of Medicine and director of the Center for Infectious Disease at Stellenbosch University, Cape Town, South Africa. "Cost for hospitalization increased from 29 percent to 51 percent of total costs as antiretroviral therapy adherence decreased, and this increase explains the difference in total mean monthly heath care costs from the lowest to the highest antiretroviral therapy adherence quartile."

Researchers conducted a cohort study to determine the effect of antiretroviral therapy adherence on direct health care costs among 6,833 HIV-infected adults. Study participants were enrolled in Aid for AIDS, a private-sector HIV/AIDS disease management program in South Africa between 2000 and 2006. Nachega, along with colleagues from the Bloomberg School, University of Cape Town and Aid for AIDS, averaged monthly direct health care costs and categorized pharmacy claim adherence in quartiles, from 1 to 4. Independent effects of patient characteristics on monthly total health care costs were assessed with advanced health econometrics models.

"The cost savings are largely related to less hospital use. The threat is that budgets for hospitals are often divorced from budgets for outpatient AIDS treatment. In fragmented health systems it is difficult for the outpatient administrator to rationalize investments that lower the costs for hospitals. A broader view is necessary to improve patient care and save money," said David Bishai, MD, PhD, co-author of the study and associate professor in the Bloomberg School's Department of Population, Family and Reproductive Health.

"Effective, practical intervention strategies to promote, as well as to proactively monitor antiretroviral therapy adherence, are badly needed as they may save direct health care costs by decreasing patient's morbidity and mortality and are likely to be cost-effective in the long-term," added Nachega.


'/>"/>

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Related medicine news :

1. Clinical trial of antiretroviral-based HIV prevention strategies for women now under way
2. HIV integrase inhibitor effective for patients beginning antiretroviral treatment
3. Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
4. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
5. Researchers estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa
6. Rare case explains why some infected with HIV remain symptom free without antiretroviral drugs
7. Increasing access to antiretroviral drugs would drastically cut AIDS deaths in South Africa
8. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
9. Antiretroviral Drugs May Prevent Vaginal Transmission of HIV
10. Music therapy can assist toddlers communication rehabilitation process
11. UV LED therapy shows promising results in preventing focal seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... In response to recent growth and a demand ... and Blindness (NELV&B) , announces the opening of a new low vision showroom in ... impairments to get assessments, hands-on experience and training with low vision and blindness devices ...
(Date:5/1/2016)... ... May 02, 2016 , ... Avid collector, Andrew Hawley ... Post Pavilion in Columbia, Maryland concert posters. Dail Beeghley hit a poster design ... on August 16. According to Hawley, “The Pavilion was built to host the ...
(Date:5/1/2016)... ... 01, 2016 , ... ProBrand Reveal Volume 2 is a set of versatile and smooth logo ... keyframeless animations, users can easily create a unique logo reveal in just a matter of ... presets. Use these title presets to add a uniquely animated logo to any photos or ...
(Date:4/30/2016)... (PRWEB) , ... May 01, 2016 , ... Serenity Recovery, ... to rehabilitation, has produced a new video that focuses on one of the more ... recent sessions and clips from interviews with a participating patients and the Yoga class ...
(Date:4/30/2016)... ... 30, 2016 , ... The Hacking Medicine Institute ... critically evaluate and rank health-focused applications and connected devices for better disease monitoring ... and accurate information to help accelerate patient and provider adoption of clinically proven ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... titled, "Skincare Devices Market - Global Industry Analysis, Size, ... to the report, the global skincare devices market was ... anticipated to expand at a CAGR of 10.1% from ... 2023. Browse the full Skincare Devices Market (Treatment ...
(Date:4/27/2016)... 27, 2016  Bayer Animal Health today announced ... the University of Florida College of Veterinary Medicine, ... in Communication Award (BECA). Brittany was selected from ... a total of $70,000 in scholarship funds through ... Bayer has provided a total of $232,500 in ...
(Date:4/27/2016)... 27, 2016 Oasmia Pharmaceutical ... of a new generation of drugs within human ... results for Paclical/Apealea in the Phase III study ... epithelial ovarian cancer. These preliminary results showed non-inferiority ... with carboplatin versus Taxol in combination with carboplatin. ...
Breaking Medicine Technology: